These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 7371359)

  • 21. Proteasome-dependent degradation of intracellular carbamylated proteins.
    Desmons A; Okwieka A; Doué M; Gorisse L; Vuiblet V; Pietrement C; Gillery P; Jaisson S
    Aging (Albany NY); 2019 Jun; 11(11):3624-3638. PubMed ID: 31170093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
    Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
    Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potassium cyanate as an inhibitor of the sickling of erythrocytes in vitro.
    Cerami A; Manning JM
    Proc Natl Acad Sci U S A; 1971 Jun; 68(6):1180-3. PubMed ID: 5288366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of protein concentration on the binding of drugs to human serum albumin--I. Sulfadiazine, salicylate and phenylbutazone.
    Boobis SW; Chignell CF
    Biochem Pharmacol; 1979 Mar; 28(6):751-6. PubMed ID: 454474
    [No Abstract]   [Full Text] [Related]  

  • 25. Valproate plasma protein binding in the uremic condition.
    Brewster D; Muir NC
    Clin Pharmacol Ther; 1980 Jan; 27(1):76-82. PubMed ID: 6985855
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyanate as a hemolytic factor.
    Mun KC; Kim HC; Kwak CS
    Ren Fail; 2000 Nov; 22(6):809-14. PubMed ID: 11104168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein binding of salicylate and quinidine in plasma from patients with renal failure, chronic liver disease and chronic respiratory insufficiency.
    Pérez-Mateo M; Erill S
    Eur J Clin Pharmacol; 1977 Mar; 11(3):225-31. PubMed ID: 856605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein carbamylation in kidney disease: pathogenesis and clinical implications.
    Kalim S; Karumanchi SA; Thadhani RI; Berg AH
    Am J Kidney Dis; 2014 Nov; 64(5):793-803. PubMed ID: 25037561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Longitudinal Changes in Protein Carbamylation and Mortality Risk after Initiation of Hemodialysis.
    Kalim S; Trottier CA; Wenger JB; Wibecan J; Ahmed R; Ankers E; Karumanchi SA; Thadhani R; Berg AH
    Clin J Am Soc Nephrol; 2016 Oct; 11(10):1809-1816. PubMed ID: 27445162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein binding of drugs in plasma from patients with acute renal failure.
    Andreasen F
    Acta Pharmacol Toxicol (Copenh); 1973; 32(6):417-29. PubMed ID: 4800749
    [No Abstract]   [Full Text] [Related]  

  • 31. Chronic increase of urea leads to carbamylated proteins accumulation in tissues in a mouse model of CKD.
    Pietrement C; Gorisse L; Jaisson S; Gillery P
    PLoS One; 2013; 8(12):e82506. PubMed ID: 24324801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.
    Dengler TJ; Robertz-Vaupel GM; Dengler HJ
    Eur J Clin Pharmacol; 1992; 43(5):491-9. PubMed ID: 1282889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased drug binding in serum from patients with chronic hepatic disease.
    Wallace S; Brodie MJ
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):429-32. PubMed ID: 971706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carbamylation of erythrocyte membrane proteins: an in vitro and in vivo study.
    Trepanier DJ; Thibert RJ; Draisey TF; Caines PS
    Clin Biochem; 1996 Aug; 29(4):347-55. PubMed ID: 8828965
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carbamylation inhibits the ferroxidase activity of caeruloplasmin.
    Roxborough HE; Millar CA; McEneny J; Young IS
    Biochem Biophys Res Commun; 1995 Sep; 214(3):1073-8. PubMed ID: 7575512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylisocyanate and actin polymerization: the in vitro effects of carbamylation.
    Kuckel CL; Lubit BW; Lambooy PK; Farnsworth PN
    Biochim Biophys Acta; 1993 Mar; 1162(1-2):143-8. PubMed ID: 8448178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantification of carbamylated albumin in serum based on capillary electrophoresis.
    Delanghe S; Moerman A; Pletinck A; Schepers E; Glorieux G; Van Biesen W; Delanghe JR; Speeckaert MM
    Electrophoresis; 2017 Sep; 38(17):2135-2140. PubMed ID: 28556931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of salicylate binding to normal plasma by extracts of uremic fluids.
    Roman S; Gulyassy PF; Depner TA
    Am J Kidney Dis; 1984 Sep; 4(2):153-61. PubMed ID: 6475946
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of erythropoietin activity by cyanate.
    Park KD; Mun KC; Chang EJ; Park SB; Kim HC
    Scand J Urol Nephrol; 2004; 38(1):69-72. PubMed ID: 15204430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.